Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 5/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138435 | 0.87 | RIPK1 (0.47) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9891847 | 0.83 | GLS (0.41) | CA1CA2CA9CA12NOTUM | |
| SCHEMBL23945848 | 0.79 | GBA1 (0.44) | MAPTL3MBTL1 | |
| SCHEMBL19497747 | 0.78 | MAP3K8 (0.34) | CA1CA2CA9CA12 | |
| SCHEMBL21992355 | 0.78 | MAPT (0.39) | MAPT | |
| SCHEMBL16576128 | 0.78 | FNTA (0.36) | MAPTCA1CA2CA9CA12 | |
| SCHEMBL24095996 | 0.76 | EPHX2 (0.47) | — | |
| SCHEMBL21672550 | 0.76 | MAP3K8 (0.36) | — | |
| SCHEMBL25138443 | 0.74 | NPC1 (0.39) | MIFL3MBTL1NPC1POLB | |
| SCHEMBL8931479 | 0.73 | CYP4F2 (0.33) | NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20200297876-A1 | PSMA ligands for imaging and endoradiotherapy | Technische Universität München (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | KLK3, FOLH1, EEA1 | MAPT 2125/4885CA1 1328/4885CA2 3376/4885 |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | ASIC1, ABL1, CA9 | MAPT 424/4885CA1 8/4885CA2 24/4885 |
| US-20200297876-A1 | PSMA ligands for imaging and endoradiotherapy | KLK3, FOLH1, EEA1 | MAPT 2125/4885CA1 1328/4885CA2 3376/4885 |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | MAGT1, GALNT1, NMT1 | MAPT 3017/4885CA1 4089/4885CA2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.